Fenolip

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenolip

What is Fenolip? Overview

Property Description
Active ingredient Fenofibrate (converted to fenofibric acid)
Form Oral tablets or capsules (often micronized)
Pharmacological class Fibrate (Antihyperlipidemic Agent)
General purpose Correcting imbalances in blood lipids (dyslipidemia)
Origin Synthetic compound

Fenolip: Definition and Pharmacological Classification

Fenolip is a synthetic, prescription-only medication specifically classified as an Antihyperlipidemic Agent belonging to the fibrate pharmacological class. The active component is Fenofibrate, a fibric acid derivative that works systemically to modify the body’s lipid profile. Fenofibrate is utilized for its efficacy in lipid management. The conclusion for patients is that this medication helps manage the fat balance in the blood, an action intended for addressing lipid irregularities.


Composition, Forms, and Differentiation

Fenolip is a single-ingredient product formulated for oral administration, typically supplied as tablets or capsules. The Fenofibrate compound acts as a prodrug, meaning it converts to its active form, fenofibric acid, after ingestion. The formulation frequently utilizes micronized or nanocrystallized preparations; this specialized reduction in particle size is designed to enhance the drug's absorption and overall bioavailability. This optimized formulation ensures reliable systemic delivery of the active ingredient, differentiating it from older, less efficiently absorbed fenofibrate compounds.


General Purpose as a Lipid-Modifying Agent

The general purpose of Fenolip is to serve as a lipid-modifying therapy aimed at correcting irregular fat levels, particularly in individuals with dyslipidemia. A typical use scenario for this class of medicine involves its role in managing patients with persistently elevated triglycerides and improving the overall ratio of cholesterol components. This medication generally helps by reducing elevated triglycerides and consistently elevating the levels of beneficial High-Density Lipoprotein (HDL) cholesterol, thereby supporting the maintenance of a healthier lipid status.

Regulatory References

  1. Fenofibrate: MedlinePlus Drug Information
  2. FENOFIBRATE tablet - DailyMed - NIH

What side effects are possible with Fenolip?

Fenolip: Official Safety Profile and Adverse Reactions

The safety profile of Fenolip (Fenofibrate) outlines known adverse reactions classified by frequency and system involvement, as documented in official regulatory labeling. These classifications establish the expected range of effects and are non-advisory.

Adverse reactions are grouped by System-Organ Classes (SOC) including Gastrointestinal, Hepatobiliary, Musculoskeletal, Nervous System, and Vascular disorders.

Frequency Category Representative Adverse Reactions
Common (1 in 10 to 1 in 100) Headache, gastrointestinal discomfort (e.g., abdominal pain), and elevated liver transaminases (ALT/AST).
Uncommon (1 in 100 to 1 in 1,000) Pancreatitis, cholelithiasis (gallstones), thromboembolism, and muscle disorders (myalgia).
Rare (1 in 1,000 to 1 in 10,000) Hepatitis, rhabdomyolysis (severe muscle breakdown), and decreased blood cell counts.

Serious adverse reactions documented in regulatory sources include Rhabdomyolysis, Hepatitis, and Pancreatitis.

Safety notes from regulatory authorities impose strict constraints regarding use in special populations and pre-existing conditions. Fenolip is contraindicated in individuals with severe renal impairment and active liver disease (including persistent, unexplained liver function abnormalities). Furthermore, safety and effectiveness have not been established for pediatric patients.

Specific monitoring is required for certain effects; for example, liver transaminase elevations require periodic monitoring, especially during the initial year of treatment. The risk of serious muscle toxicity is noted to be generally higher at the initiation of therapy.

Overdose and Emergency Response

Fenolip Overdose and When to Seek Help

Regulatory information on Fenolip (Fenofibrate) overdosage is characterized by the need for prompt medical management rather than a specific set of documented clinical symptoms. Official prescribing information notes that only anecdotal cases of overdosage have been reported, and a specific, expected symptom profile is not detailed in the Overdosage section. For this reason, immediate professional medical attention is required for observation and supportive care in all cases of suspected overdose.

Required Emergency Actions

Since no specific antidote is known for Fenofibrate overdosage, treatment is officially defined as symptomatic and supportive. Management mandates the monitoring of vital signs and the observation of the patient’s clinical status under medical supervision. Standard precautions to maintain the airway must also be observed.

Supportive Measures and Constraints

If clinically appropriate, efforts may be made to eliminate unabsorbed drug through procedures such as gastric lavage or emesis. A critical constraint noted in regulatory labeling is that hemodialysis should not be considered as an effective measure because the active metabolite, fenofibric acid, is highly bound to plasma proteins. The entire management strategy is centered on structured supportive medical supervision.

Therapeutic Uses of Fenolip

What Fenolip Treats: Main Uses and Benefits

Fenolip is applied across domains where additional symptomatic support for systemic fat imbalances is needed and provides support that helps ease the overall symptom burden in conditions presenting with systemic discomfort. The medication is indicated for use alongside dietary and lifestyle management to address conditions characterized by high blood fats, including primary hypercholesterolemia, mixed dyslipidemia, and elevated triglycerides.

This medication may assist with maintaining functional stability as part of the overall management plan for these chronic conditions. It is commonly used when short-term symptomatic assistance for fat level management is needed to address symptoms related to systemic imbalance, particularly the hidden risks posed by high blood fats.

“This management supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Lipid Imbalance

The primary benefit is assisting with the management of high blood fats by helping to lower unhealthy cholesterol (LDL) and triglycerides, and by supporting an increase in protective HDL cholesterol. This management may play a role in supporting the reduction of risk for adverse health conditions.

Eligibility and Restrictions for Use

Who can and cannot use Fenolip?

The population eligibility for Fenolip (Fenofibrate) is strictly governed by regulatory classifications concerning organ function, pre-existing conditions, and age.

Classification Condition or Population
Contraindicated Active liver disease (including primary biliary cirrhosis)
Contraindicated Severe renal impairment (eGFR <30 mL/min/1.73m^2)
Contraindicated Pre-existing gallbladder disease
Contraindicated Nursing mothers (Lactation)
Contraindicated Known hypersensitivity to fenofibrate or fenofibric acid

Fenolip is approved for use in adults (ge 18 years). However, use is not recommended in the pediatric population as safety and efficacy have not been established. Geriatric patients may use the medicine, but the determination of the appropriate use must be based upon an assessment of renal function.

Patients with mild to moderate renal impairment are eligible only under restricted use, which requires initial modification and careful monitoring. Furthermore, secondary causes of high blood fats, such as uncontrolled diabetes or hypothyroidism, must be addressed and adequately treated before Fenolip therapy can be initiated.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Fenolip

Category Official Interaction Entities
Pharmacokinetic Interactions Fenofibric acid is a weak inhibitor of CYP2C9.
Pharmacodynamic Interactions HMG-CoA Reductase Inhibitors (Statins) increase the additive risk of myopathy and rhabdomyolysis.
Immunosuppressants (e.g., Cyclosporine) may lead to an increased risk of nephrotoxicity/renal dysfunction.
Exposure-Modifying Substances Oral Coumarin Anticoagulants (e.g., Warfarin) are potentiated, increasing the anticoagulant effect.
Food / Timing Requirements Bile Acid Sequestrants (e.g., Cholestyramine) require separation (must be administered at least 1 hour before or 4 to 6 hours after).
Certain formulations must be administered with food to achieve optimal absorption and systemic exposure.
Population-Specific Notes The interaction-related risk of myopathy is increased in geriatric patients and those with renal impairment.

Interaction scope

Medicinal product categories with documented interactions: HMG-CoA Reductase Inhibitors, Oral Coumarin Anticoagulants, Immunosuppressants, Bile Acid Sequestrants.

Specific interacting medicines (if explicitly listed): Warfarin, Cyclosporine, Cholestyramine.

Mechanistic basis of interactions (only if stated in label): Weak inhibition of CYP2C9 (pharmacokinetic); Additive risk (pharmacodynamic); Interference with absorption (physical).

Timing-based interaction rules (if applicable): Co-administration with bile acid sequestrants must be separated by administering Fenolip at least 1 hour before or 4 to 6 hours after the sequestrant.

Population-specific interaction notes (if applicable): The interaction-related risk of muscle toxicity is increased in geriatric patients and patients with renal impairment.

Interaction-related restrictions: Restrictions apply to co-administration with bile acid sequestrants (mandatory time separation) and coumarin anticoagulants (requires monitoring due to potentiation).


Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Interactions are classified as clinically significant requiring monitoring, precautionary use due to additive risk, or timing-related mandates.

Regulatory basis (EMA / FDA / etc.): Information is based on FDA Prescribing Information and EMA Summary of Product Characteristics.

Interaction-context constraints (as defined in official documents): Certain formulations must be taken with food to ensure adequate systemic exposure, representing a mandatory drug-food context constraint.


Resulting interaction structure

Official interaction statements:

  • Fenofibric acid's weak inhibition of CYP2C9 potentiates the anticoagulant effect of coumarin anticoagulants like Warfarin.
  • Co-administration with statins or cyclosporine increases the additive risk of muscle toxicity or renal dysfunction, respectively.
  • Co-administration with bile acid sequestrants reduces Fenolip's absorption and requires separation by at least 1 hour before or 4 to 6 hours after the sequestrant.

Connection to the overall interaction profile: The regulatory documents establish a profile defined by a pharmacokinetic potentiation effect on anticoagulants, an additive pharmacodynamic risk with statins and immunosuppressants, and a physical absorption interference requiring mandatory timing separation for certain co-administered drugs.

Mechanism of Action

Activation of PPAR-Alpha: The Molecular Switch

Fenolip's active form, fenofibric acid, functions as an agonist of the Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha), a nuclear receptor . This activation acts as a molecular switch, leading to transcriptional modulation—the upregulating and downregulating of genes in the liver that govern lipid metabolism. This mechanism initiates the entire chain of physiological effects by changing the expression of key metabolic enzymes and apolipoproteins.


Mechanism for Accelerated Fat Clearance

The genomic effects triggered by PPAR-alpha agonism increase the production of Lipoprotein Lipase (LPL) and simultaneously reduce the synthesis of Apolipoprotein C-III (ApoC-III), an LPL inhibitor. This dual-action approach accelerates the catabolism of triglyceride-rich lipoproteins (like VLDL) and their removal from the bloodstream.


Mechanism for Increased HDL Production

In addition to affecting triglyceride metabolism, the activation of PPAR-alpha increases the synthesis of Apolipoproteins A-I and A-II, which are the structural components for HDL cholesterol. This action promotes the formation of new HDL particles and enhances the process of reverse cholesterol transport, resulting in the systemic modulation of the lipid profile.

Dosage and Administration Information

Official Administration Guidelines

Fenolip (fenofibrate) is administered as a single oral dose once daily. The specific dosage form is either a tablet or a capsule, which must be swallowed whole and is not to be crushed or chewed.

The standard adult dosing regimen for mixed dyslipidemia is described as involving a single daily dose ranging from 105 mg to 160 mg fenofibrate equivalent, with the maximum dose being formulation-dependent. The dose is individualized and adjusted based on lipid levels measured at intervals of four to eight weeks.

Crucially, the medication’s required relationship with food varies by formulation; certain tablets or capsules are taken with a meal, while others are indicated to be taken independently of food. Furthermore, the administration is separated from bile acid binding resins by at least 1 hour before or 4 to 6 hours after the resin to prevent absorption interference. In the event of a missed dose, guidelines indicate skipping the missed dose and resuming treatment with the next scheduled dose.

Dosage adjustment is mandatory for certain populations. Patients with mild to moderate renal impairment require a dose reduction, and the use of Fenolip is not recommended for those with severe renal impairment. Conversely, for the geriatric population, dose selection is based primarily on an assessment of renal function. The safety and efficacy of the medicine have not been established for pediatric patients under 18 years of age. Treatment is generally long-term but is discontinued if a sufficient therapeutic response is not achieved after two to three months at the established maximum dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Fenolip

This overview describes the types of scientific research conducted on Fenolip (fenofibrate) to evaluate its use in conditions associated with systemic fat imbalances. The information presented here is drawn from official regulatory reviews and major peer-reviewed clinical trials, and does not constitute medical advice or a recommendation for use.


Evidence Base for Managing Severe Triglyceride Elevation

Research has examined Fenolip in individuals with very high levels of triglycerides (a type of fat in the blood), often exceeding 500 mg/dL. These investigations included both short-term comparative controlled trials and observational studies. The findings describe patterns observed in the studies where studies monitored reported changes in the measured levels of Triglycerides. What remains uncertain is how these documented changes in lab results translate directly to outcomes related to the incidence of a complication like pancreatitis, which may be linked to extremely high triglycerides. Long-term effects are not fully established regarding the consistency of these lipid changes beyond the initial observation periods.


Evidence Base for Mixed Dyslipidemia and Hypercholesterolemia

Research has extensively evaluated Fenolip in research settings related to conditions involving mixed dyslipidemia (a combination of high cholesterol and high triglycerides), as part of research investigating dietary and lifestyle management. This evidence base is built upon several Randomized Controlled Trials (RCTs). Studies monitored changes in lipid biomarkers, and these findings data show patterns related to changes in the lipid biomarkers (Triglycerides and HDL-C) relevant to the conditions studied.

Focus on Cardiovascular Event Outcomes

The primary analysis of these trials did not report consistent findings related to major cardiovascular events across the entire group studied. However, research describes that subgroup analyses identified specific cohorts of participants—particularly those who entered the study with a pattern of very high triglycerides and low HDL cholesterol—where patterns of difference in cardiovascular event rates was observed in some studies. Certainty remains low for applying these findings broadly, as the results were not achieved in the primary outcomes across all studied groups.

Frequently Asked Questions (FAQ)

Common questions about Fenolip (FAQ)

Q: Is Fenolip the same kind of drug as other popular medicines for its purpose?

A: Fenolip's active ingredient, fenofibrate, belongs to a class of medications called fibric acid derivatives or fibrates. Its primary mechanism involves activating a specific receptor, PPAR alpha, to modify the body's fat metabolism. This approach is distinct from other major types of lipid-lowering drugs, such as statins.

Q: Why is Fenolip used by some people if there are other options available?

A: Official information indicates that Fenolip is used as an addition to diet, specifically to manage severe hypertriglyceridemia (very high levels of fat in the blood) and mixed dyslipidemia. Its approved profile indicates a focus on reducing triglycerides and increasing beneficial HDL cholesterol, which differentiates its use from other therapies.

Q: How quickly can a person expect to notice any effects from Fenolip?

A: The effects of Fenolip are not immediate. Health professionals assess the response by checking lipid levels, which are typically measured at intervals of four to eight weeks after initiating therapy. Regulatory guidelines state that treatment is typically discontinued if an adequate therapeutic response is not observed after two months.

Q: Can Fenolip cause weight gain or loss?

A: Regulatory information indicates that weight gain has been reported as an adverse reaction, though the exact incidence is not known. Weight loss is sometimes mentioned as a symptom that may accompany a serious adverse event, rather than being a direct side effect of the medicine.

Q: Is it true that Fenolip can affect sleep?

A: Yes, official safety data lists insomnia (difficulty sleeping) as a common side effect observed in clinical trials for fenofibrate. Any concerns about changes in sleep patterns should be discussed with the individual's health professional.

Q: Can Fenolip be taken with common pain relievers like Tylenol (acetaminophen) or Advil (ibuprofen)?

A: Fenolip has the potential to affect the way other drugs are processed by the body's metabolism. Due to this, the co-administration of all other medications, including common over-the-counter pain relievers, requires discussion with a health professional.

Q: What types of foods or drinks should be avoided while taking Fenolip?

A: Official information requires that Fenolip be used alongside an appropriate lipid-lowering diet. Furthermore, caution is advised regarding heavy alcohol ingestion. This is because alcohol is cited as a predisposing factor that may increase the risk of certain side effects, like muscle damage, and may also worsen underlying lipid disorders.

Q: Does Fenolip interact with alcohol?

A: Yes, regulatory information advises caution regarding alcohol consumption. Heavy alcohol ingestion is cited as a predisposing factor that may increase the risk of adverse events such as myopathy (muscle damage) and can worsen underlying conditions like liver disease or high triglycerides.

Q: Are there any supplements that people should be careful about taking with Fenolip?

A: Fenolip is known to potentiate (intensify the effect of) certain blood thinners, such as coumarin anticoagulants. Caution is advised regarding any herbal or dietary supplement that may affect blood clotting. Individuals must discuss all supplements with a health professional before taking Fenolip.

Q: Is Fenolip considered safe during pregnancy or while breastfeeding?

A: Official regulatory documents indicate that Fenolip is contraindicated (not recommended for use) in nursing mothers. For use during pregnancy, the medication should only be considered if the potential benefit is judged by a health professional to outweigh the potential risks to the fetus.

Q: Does Fenolip have an impact on blood sugar levels?

A: Fenolip is often used in patients who have diabetes mellitus. Regulatory guidance indicates that patients with underlying diabetes should have their condition stabilized before initiating or continuing Fenolip treatment, suggesting that blood glucose monitoring is part of the clinical management.

Q: Is Fenolip used for anything other than its main approved purpose?

A: The FDA-approved uses for Fenolip are strictly limited to the treatment of specific, defined lipid abnormalities: severe hypertriglyceridemia and mixed dyslipidemia. Regulatory documents do not address or recommend any other uses.

Q: What is the purpose of the long-term studies conducted on Fenolip?

A: Major long-term clinical studies, such as the FIELD trial, were conducted to gather data on the effects of fenofibrate therapy on long-term clinical outcomes. The primary focus of these investigations was to evaluate the impact on events related to coronary heart disease.

Q: Can Fenolip cause changes in mood or energy levels?

A: Changes in mood and energy are possible. Regulatory safety data lists common effects like dizziness and insomnia. Other reported adverse effects in the psychiatric category include depression, anxiety, and nervousness (incidence is not always reported).

Q: Do I need to change my diet while on Fenolip?

A: Yes, official prescribing information states that Fenolip is to be used as an adjunct to diet. Individuals must be placed on an appropriate lipid-lowering diet before starting the medication and are directed to continue maintaining this diet throughout the course of treatment.

Q: Is Fenolip available as a generic medicine?

A: Yes, the active ingredient, fenofibrate, is widely available as a generic medicine under various formulations and brand names, which is supported by official regulatory documentation.

Q: Can taking Fenolip affect the results of common lab tests?

A: Yes, taking Fenolip is known to affect several standard lab test results. These changes can include reversible increases in serum creatinine (a measure of kidney function) and liver enzymes, as well as mild-to-moderate decreases in blood cells such as hemoglobin and white blood cell counts.

Q: What is the risk of a severe allergic reaction to Fenolip?

A: Although uncommon, Fenolip carries a risk of severe and sometimes life-threatening allergic reactions. These serious reactions reported include anaphylaxis (a sudden, severe reaction), angioedema (deep tissue swelling), and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and DRESS.

Q: How long does Fenolip stay in the system after the last dose?

A: Fenofibric acid, the active form of the medicine, has a terminal half-life of approximately 20 to 23 hours. This indicates that it typically takes about five days of regular dosing to achieve stable drug levels in the bloodstream.

Q: Is it normal to feel a bit nauseous after starting Fenolip?

A: Official safety data lists nausea as a less common side effect reported in clinical trials. However, persistent or severe nausea should be discussed with a health professional, as it may be a symptom associated with a serious adverse reaction.

Q: Why are people with a history of certain medical conditions advised against Fenolip?

A: Fenolip is contraindicated in people with specific pre-existing conditions because the risk of harm is increased. For example, it is advised against in severe renal impairment because the drug can accumulate, and in gallbladder disease because the drug can raise the risk of gallstone formation.

Q: How important is it to take Fenolip at the same time every day?

A: Fenolip is intended to be taken once daily. Taking the medicine at approximately the same time each day is recommended to help ensure consistent drug levels in the bloodstream and to maintain a steady therapeutic effect.

Q: Can Fenolip make me feel dizzy or lightheaded?

A: Yes, dizziness is listed in the official safety profile as a common adverse reaction, meaning it was reported to occur in 1% to 10% of patients in clinical trials. Any persistent dizziness should be discussed with the individual's healthcare provider.

Q: Does taking Fenolip make you more sensitive to the sun?

A: Yes, the official safety profile includes increased sensitivity of the skin to sunlight (photosensitivity) as a reported side effect. Due to this potential effect, sun exposure precautions are often part of clinical guidance.

Q: What does 'contraindication' mean in the context of Fenolip?

A: A contraindication is a core term in regulatory documents used to denote a condition or factor that absolutely forbids the use of the drug. In the context of Fenolip, this includes conditions like active liver disease or severe renal impairment, where using the drug would put the patient at an unacceptably high risk.

How should Fenolip be stored and disposed of?

How to Store and Dispose of Fenolip?

Storing Fenolip (fenofibrate) correctly is essential for maintaining its stability. Official regulatory guidelines require this medication to be stored at Controlled Room Temperature, defined as 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).

It is critical to keep Fenolip in its original, closed container to protect it from moisture, and it must be kept from freezing. To prevent accidental ingestion, always store the medication securely out of the reach of children and pets.

Disposal of unused or expired Fenolip must be done in accordance with local regulations. If a drug take-back program is unavailable, it should be removed from the container, mixed with an undesirable substance like dirt or coffee grounds, sealed in a bag or container, and placed in the household trash. It should not be flushed down a toilet or sink to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenolip found in:

A-Z Index: